Part-Time Marketing Director In North West - Chris Bunniss




Chris is highly personable, driven and hands-on with core strengths in global and local strategy development, execution & innovation – achieving operational and commercial traction across consumer healthcare, OTC & Pharma. He also has considerable experience in merger & acquisition.  18 years with Boots and 17 years with SSL International - where he was global and UK marketing director of Durex and Scholl bring a deep understanding of the consumer healthcare market from both a consumer and trade perspective.  Established successful marketing consultancy.  Strong communication and leadership skills and a positive consultative style. Worked at board level as well as with small business owners.



Bunniss Associates Limited
Successful marketing consultancy. HRA PHARMA – due diligence on Compeed acquisition; strategic marketing plan development; new geographies go-to-market strategy. 3 year contract with Boeheringer Ingelheim in Germany (#8 global OTC company) - global category expansion; new geographies evaluation; accelerating innovation; due diligence on global acquisition. Ceuta Healthcare – positioning for new market entrant into niche OTC category, double award winner at OTC awards. Canonbury Products – SimplyFeet direct-to-consumer business expansion

SSL International
Led the commercial acquisition function; senior global & UK marketing roles. Durex global sales increased from £130m - £248m and Scholl from £79m - £128m during tenure. Innovation drove brand shares to highest ever levels. Led expansion of Durex from ‘Family Planning’ to ‘Sexual Wellbeing’. Successful ‘hero product’ strategy for Scholl

Boots Group
Launched and established market leading positions for BHI brands in Central & Eastern Europe. Led team of 3 brand managers responsible for the E45 brand; successfully expanded the E45 brand with the launch of Lotion, Wash, Bath and Sun E45. Marketing and brand management roles on Brufen in International Pharmaceutical Marketing
Get In Touch
Let's Talk